A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

Pfizer23 enrolled

Overview

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danuglipron The total number of weeks of the study is about 15 (about 4 months).

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Obesity

Interventions

DanuglipronDRUG

Danuglipron oral tablets

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key Inclusion Criteria: * 18 years of age or older * Body mass index (BMI) of ≥25.0-45.4 kg/m2; and a total body weight \>50 kg (110 lb) Key Exclusion Criteria: * Evidence or history of any clinically significant medical conditions or laboratory abnormality * Any condition possibly affecting drug absorption * Known intolerance/hypersensitivity to a GLP-1R agonist

Locations (1)

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron

Time frame: Predose to 24 hours post danuglipron administration

Steady-state maximum observed concentration (Cmax) for danuglipron

Time frame: Predose to 24 hours post danuglipron administration

Steady-state time to reach maximum observed concentration (Tmax) for danuglipron

Time frame: Predose to 24 hours post danuglipron administration